Synonym
Ursodoxicoltaurine; Tauroursodeoxycholic Acid; TUDCA; Tauroursodeoxycholate
IUPAC/Chemical Name
2-(3α,7β-dihydroxy-5β-cholan-24-amido)ethane-1-
sulfonic acid
InChi Key
BHTRKEVKTKCXOH-LBSADWJPSA-N
InChi Code
InChI=1S/C26H45NO6S/c1-16(4-7-23(30)27-12-13-34(31,32)33)19-5-6-20-24-21(9-11-26(19,20)3)25(2)10-8-18(28)14-17(25)15-22(24)29/h16-22,24,28-29H,4-15H2,1-3H3,(H,27,30)(H,31,32,33)/t16-,17+,18-,19-,20+,21+,22+,24+,25+,26-/m1/s1
SMILES Code
O[C@@H]1CC[C@@]2(C)[C@@](C[C@H](O)[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@]4([H])[C@H](C)CCC(NCCS(=O)(O)=O)=O)([H])C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Tauroursodeoxycholate (Tauroursodeoxycholic acid) is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK.
In vitro activity:
As shown in Fig. 3, the percentages of TUNEL-positive apoptotic cells were increased up to 60% in groups exposed to tunicamycin compared with the TUN only group; however, there was no change when cells were exposed to TUDCA alone. As expected, pretreatment with TUDCA reduced the occurrence of apoptosis in tunicamycin-treated DRG neurons (Fig. 3), indicating the neuroprotective role of TUDCA.
Reference: Exp Ther Med. 2022 Jun 10;24(2):509. https://pubmed.ncbi.nlm.nih.gov/35837048/
In vivo activity:
Compared with the CON group, TUDCA supplementation improved the intestinal morphology by increasing the V/C ratios in jejunum and ileum (P < 0.05) (Fig. 1A, B). In addition, PAS staining results showed that TUDCA supplementation increased the number of goblet cells secreting mucopolysaccharides in jejunum and ileum (P < 0.05, Fig. 1C and D). Furthermore, the expression of TJ proteins, such as OCC and Claudin-1, was higher in jejunum of piglets supplemented with TUDCA (P < 0.05, Fig. 2A, B). Accordingly, the intestinal permeability was reduced, which was manifested by the decreased serum LPS and DAO levels (P < 0.05, Fig. 2C, D). These above results suggested that dietary supplementation of TUDCA enhanced intestinal barrier function of weaned piglets.
Reference: J Anim Sci Biotechnol. 2022 Jun 8;13(1):73. https://pubmed.ncbi.nlm.nih.gov/35672805/
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMF |
10.0 |
20.01 |
| DMSO |
53.0 |
106.06 |
| DMSO:PBS (pH 7.2) (1:4) |
0.2 |
0.40 |
| Ethanol |
50.0 |
100.06 |
| Water |
12.5 |
25.01 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
499.71
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Chen F, Ge Z, Li N, Yu Z, Wu R, Zhao Y, He X, Cai G. TUDCA protects against tunicamycin-induced apoptosis of dorsal root ganglion neurons by suppressing activation of ER stress. Exp Ther Med. 2022 Jun 10;24(2):509. doi: 10.3892/etm.2022.11436. PMID: 35837048; PMCID: PMC9257946.
2. Kim SY, Kwon YW, Jung IL, Sung JH, Park SG. Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK via PKCα-mediated MKP-1 induction. Cardiovasc Res. 2011 Nov 1;92(2):307-16. doi: 10.1093/cvr/cvr219. Epub 2011 Aug 11. PMID: 21840882.
3. Pasha M, Kirschenman R, Wooldridge A, Spaans F, Cooke CM, Davidge ST. The Effect of Tauroursodeoxycholic Acid (TUDCA) Treatment on Pregnancy Outcomes and Vascular Function in a Rat Model of Advanced Maternal Age. Antioxidants (Basel). 2022 Jun 28;11(7):1275. doi: 10.3390/antiox11071275. PMID: 35883766; PMCID: PMC9312116.
4. Song M, Zhang F, Fu Y, Yi X, Feng S, Liu Z, Deng D, Yang Q, Yu M, Zhu C, Zhu X, Wang L, Gao P, Shu G, Ma X, Jiang Q, Wang S. Tauroursodeoxycholic acid (TUDCA) improves intestinal barrier function associated with TGR5-MLCK pathway and the alteration of serum metabolites and gut bacteria in weaned piglets. J Anim Sci Biotechnol. 2022 Jun 8;13(1):73. doi: 10.1186/s40104-022-00713-3. PMID: 35672805; PMCID: PMC9175448.
In vitro protocol:
1. Chen F, Ge Z, Li N, Yu Z, Wu R, Zhao Y, He X, Cai G. TUDCA protects against tunicamycin-induced apoptosis of dorsal root ganglion neurons by suppressing activation of ER stress. Exp Ther Med. 2022 Jun 10;24(2):509. doi: 10.3892/etm.2022.11436. PMID: 35837048; PMCID: PMC9257946.
2. Kim SY, Kwon YW, Jung IL, Sung JH, Park SG. Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK via PKCα-mediated MKP-1 induction. Cardiovasc Res. 2011 Nov 1;92(2):307-16. doi: 10.1093/cvr/cvr219. Epub 2011 Aug 11. PMID: 21840882.
In vivo protocol:
1. Pasha M, Kirschenman R, Wooldridge A, Spaans F, Cooke CM, Davidge ST. The Effect of Tauroursodeoxycholic Acid (TUDCA) Treatment on Pregnancy Outcomes and Vascular Function in a Rat Model of Advanced Maternal Age. Antioxidants (Basel). 2022 Jun 28;11(7):1275. doi: 10.3390/antiox11071275. PMID: 35883766; PMCID: PMC9312116.
2. Song M, Zhang F, Fu Y, Yi X, Feng S, Liu Z, Deng D, Yang Q, Yu M, Zhu C, Zhu X, Wang L, Gao P, Shu G, Ma X, Jiang Q, Wang S. Tauroursodeoxycholic acid (TUDCA) improves intestinal barrier function associated with TGR5-MLCK pathway and the alteration of serum metabolites and gut bacteria in weaned piglets. J Anim Sci Biotechnol. 2022 Jun 8;13(1):73. doi: 10.1186/s40104-022-00713-3. PMID: 35672805; PMCID: PMC9175448.
1: WHO Drug Information, Vol. 34, No. 2, 2020
2. Chen F, Ge Z, Li N, Yu Z, Wu R, Zhao Y, He X, Cai G. TUDCA protects against tunicamycin-induced apoptosis of dorsal root
ganglion neurons by suppressing activation of ER stress. Exp Ther Med. 2022 Jun 10;24(2):509. doi: 10.3892/etm.2022.11436. PMID:
35837048; PMCID: PMC9257946.
3. Kim SY, Kwon YW, Jung IL, Sung JH, Park SG. Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression
of ERK via PKCα-mediated MKP-1 induction. Cardiovasc Res. 2011 Nov 1;92(2):307-16. doi: 10.1093/cvr/cvr219. Epub 2011 Aug
11. PMID: 21840882.
4. Pasha M, Kirschenman R, Wooldridge A, Spaans F, Cooke CM, Davidge ST. The Effect of Tauroursodeoxycholic Acid (TUDCA)
Treatment on Pregnancy Outcomes and Vascular Function in a Rat Model of Advanced Maternal Age. Antioxidants (Basel). 2022 Jun
28;11(7):1275. doi: 10.3390/antiox11071275. PMID: 35883766; PMCID: PMC9312116.
5. Song M, Zhang F, Fu Y, Yi X, Feng S, Liu Z, Deng D, Yang Q, Yu M, Zhu C, Zhu X, Wang L, Gao P, Shu G, Ma X, Jiang Q,
Wang S. Tauroursodeoxycholic acid (TUDCA) improves intestinal barrier function associated with TGR5-MLCK pathway and the alteration of serum metabolites and gut bacteria in weaned piglets. J Anim Sci Biotechnol. 2022 Jun 8;13(1):73. doi: 10.1186/s40104-
022-00713-3. PMID: 35672805; PMCID: PMC9175448
